Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2002

View Archived Issues

Menarini will market repaglinide as Prandin in Spain

Neuroprotective effects of melatonin involve modulation of brain NO

Hypothermia extends therapeutic window of antiischemic gene therapy

Transkaryotic Therapies 2001 highlights

Strong antifungal activity of SS-750 related to inhibition of fungal cytochrome P-450 enzyme

GenVec signs contract for preventive AIDS vaccine

Morphochem and Aventis partner on antibacterial research

NDA for eplerenone in hypertension accepted for filing

Green tea extract is synergistic with carbapenems against MRSA isolates

Genta initiates two trials of Genasense in combination with chemotherapy in AML and SCLC

British Biotech obtains European development & commercialization rights to MG-98

Clarinex approved by FDA for perennial allergic rhinitis and chronic idiopathic urticaria

Twelve-month results from phase III trial of Metvix PDT in basal cell carcinoma

Ruprintrivir: human pharmacokinetics and safety of a new antirhinoviral agent

Clinical program for Onco TCS expanded

Compounds with PDE5-inhibitory activity disclosed by Lilly Icos

Inhibitors of human nonpancreatic sPLA2 useful in inflammatory disease Rx

Fujisawa reveals new selective beta3-adrenoceptor agonists

Modulators of nuclear hormone receptors described in BMS patent

Factor Xa inhibitors for thromboembolic disorders synthesized at DuPont

New AstraZeneca compounds claimed for use in T-cell-mediated disorders

Boehringer Ingelheim signs on major Japanese pharmaceutical firm to copromote telmisartan

WISP-1 attenuates p53-mediated apoptosis